Gino Santini

Gino Santini has been a director since February 2012 and chairman of the board since April 2014. In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Eli Lilly and Company, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, senior vice president of corporate strategy and policy, president of U.S. operations, and president of the women’s health franchise. Mr. Santini capped his career at Eli Lilly and Company as a member of the company‚Äôs executive committee and as the Senior Vice President of Corporate Strategy and Business Development. Mr. Santini currently serves on the boards of directors of Intercept Pharmaceuticals Inc., where he is chair of the compensation committee and a member of the audit committee, Intarcia Therapeutics Inc., where he is chair of the transaction committee and a member of the audit committee, and Collegium Pharmaceuticals, Inc., where he is lead independent director, chair of the nominating and governance committee and member of the compensation committee. He is also a member of the board of direct of Allena Pharmaceuticals, Inc., where he is chair of the compensation committee and member of the audit committee, Horizon Pharma Plc., where he is also chair of the transactions committee and member of the compensation committee, and Artax Biopharma Inc. Mr. Santini is fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the University of Rochester